Wall Street Analysts Are Bullish on This Artificial Intelligence (AI) Stock -- Here's What You Need to Know
The company's results have improved since it released an updated AI model.
Upstart is making progress in the large auto and home loan makrets.
10 stocks we like better than Upstart ›
When investors think of AI stocks, Upstart (NASDAQ: UPST) may not be the first that comes to mind. However, the company has a strong claim to the title. It's harnessed the power of machine learning and data science for a new credit platform that has been more accurate at assessing creditworthiness than conventional FICO scores, according to Upstart.
As a stock, Upstart has been one of the more volatile names in the market as the business has considerable potential, but it has also struggled to turn a profit in recent years. Plus, any credit business is inherently risky, since loans could go bad if the economy sours, or Upstart's credit partners could stop buying its loans, eliminating the funding it needs to operate.
Upstart's latest earnings report offered more reasons to be optimistic. Its transaction volume jumped 102% in the first quarter to 240,706 with originations up 89% to $2.1 billion. Meanwhile, its conversion rate improved from 14% to 19.1% because of an update in its AI model that makes as many as 1 million predictions per applicant to determine whether to lend to the applicant and what interest rate to charge.
Overall, revenue jumped 67% to $213 million, and its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) improved from a loss of $20.3 million to a profit of $42.6 million.
Now, several Wall Street analysts have turned bullish on Wall Street, and some see considerable upside to the stock.
According to Tipranks, of the 11 analysts that have rated Upstart in the last three months, four analysts rate it a buy and seven call it a hold. However, the average price target for the stock is $65.33, or a 39% upside on average.
Among the analysts that are most bullish on Upstart are Peter Christiansen of Citi, who rates the stock a buy and gives it a price target of $83; Dan Dolev of Mizuho, who gives it a buy rating and a price target of $83; and Kyle Peterson of Needham, who gives it a buy rating and a price target of $70.
Christiansen has noted Upstart's increasing interest from private credit managers and improving partner network. Dan Dolev recently reiterated a buy rating after double upgrading the stock last year in response to the company's improved profitability, and it's capturing the benefits from AI in its updated model. Kyle Peterson of Needham also sees an improving funding backdrop and balance sheet at Upstart driving the stock higher.
Wall Street forecasts on their own aren't a good reason to buy the stock, but they can alert you to good buys. Upstart has its share of naysayers as well. Nearly 25% of the stock is sold short, and Goldman Sachs gave it a sell rating in February with a price target of $15.
However, Upstart's business is improving in multiple ways. In addition to the preceding numbers, the company is increasingly tapping into the auto and home loan markets, which represent the biggest addressable markets in front of it. In the first quarter, auto originations grew five times over the last year to $61 million, while home loans grew six times to $41 million. That still represents a small fraction of the company's business, but there is potential for it to get much larger.
Upstart's business model is also scalable. The tech platform fully automates more than 90% of loan applications and can therefore scale up to make more loans at a relatively low marginal cost. Operating expenses grew by just 11% in the first quarter even as fee-based revenue was up 34%.
Overall, Upstart's technology appears to give it a competitive advantage, and it's seeing momentum in customer demand and funding partnerships. If its momentum continues, its profit should rapidly improve.
With a long runway of growth, Upstart looks like a good buy.
Before you buy stock in Upstart, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Upstart wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!*
Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
Jeremy Bowman has positions in Upstart. The Motley Fool has positions in and recommends Upstart. The Motley Fool has a disclosure policy.
Wall Street Analysts Are Bullish on This Artificial Intelligence (AI) Stock -- Here's What You Need to Know was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Marriott CEO Highlights Luxury Spend Offset By Economic Uncertainty, Reduced Government And Business Travel
Marriott International (NASDAQ:MAR) reported its second-quarter fiscal 2025 earnings on Tuesday. The company's second-quarter sales reached $6.74 billion, marking a 4.7% year-on-year increase and surpassing the analyst consensus estimate of $6.64 billion. Marriott's comparable systemwide constant-dollar revenue per available room (RevPAR) grew 1.5% year-over-year, while actual dollar RevPAR saw a 1.7% in the U.S. and Canada was flat, with RevPAR edging down 0.1% in actual dollars, while international markets saw a 5.3% increase (6.1% in actual dollars). The company added roughly 17,300 net rooms during the quarter, a 4.7% increase from the end of the second quarter of 2024. Total expenses declined 5% to $5.51 billion, contributing to an adjusted EBITDA of $1.42 billion, up from $1.32 billion a year ago. Despite a 3.4% rise in operating income to $1.24 billion, the company's operating margin fell by 100 basis points to 18%. Adjusted earnings per share (EPS) of $2.65 outperformed the consensus estimate of $2.62. View more earnings on MAR At the end of the quarter, Marriott's global system totaled nearly 9,600 properties, with approximately 1,736,000 rooms. As of June 30, Marriott held $700 million in cash and equivalents. In the quarter, Marriott repurchased 2.8 million shares of common stock for $700 million. Through July 30, the company has returned over $2.1 billion to shareholders through dividends and share repurchases. CEO Anthony Capuano reported that Marriott delivered a strong second quarter, posting solid financial results and robust net rooms growth despite ongoing macroeconomic uncertainty, with luxury strength offset by weaker select service demand due to reduced government and business transient travel. Capuano noted that development activity remained strong, with nearly 32,000 rooms signed, over 70% in international markets, and a record pipeline of more than 590,000 rooms at quarter-end. Conversions accounted for about 30% of signings and openings in the first half of the year, and Marriott still expects full-year net rooms growth to approach 5%. He highlighted the launch of Series by Marriott, a new regional brand targeting the midscale and upscale segments, and its founding deal with India's Fern portfolio. Capuano also pointed to the acquisition of lifestyle brand citizenM as a key expansion, positioning Marriott better to serve guests, Bonvoy members, and owners globally. 'Our results in the second quarter underscore the resiliency of our cash-generating, asset-light business model and the strength of our brands,' he said. Outlook Marriott revised its 2025 adjusted EPS outlook to $9.85-$10.08 (prior $9.82-$10.19) versus the $10.06 analyst consensus estimate and gross fee revenue of $5.365 billion-$5.420 billion (prior $5.365 billion-$5.475 billion). The company expects third-quarter adjusted EPS of $2.31-$2.39 against an analyst consensus estimate of $2.48 and gross fee revenue of $1.310 billion-$1.325 billion. Marriott stock declined 8% year-to-date amid macroeconomic uncertainties like labor costs and travel demand fluctuations. Price Action: Marriott shares traded lower by 0.68% to $257.37 at last check Tuesday. Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? MARRIOTT INTERNATIONAL (MAR): Free Stock Analysis Report This article Marriott CEO Highlights Luxury Spend Offset By Economic Uncertainty, Reduced Government And Business Travel originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions
New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS, ME/CFS, Long COVID, and other neuroimmune disorders SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- ChronicleBio, a techbio startup focused on radically accelerating insights on neuroimmune disorders, officially launched Tuesday with a bold mission: to build the world's richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions. ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences: Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI's applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation. Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio. Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing. Together, they are tackling a critical gap in biomedical research. ChronicleBio is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development. "Entire communities of patients have been ignored for too long, not because their conditions aren't debilitating and prevalent, but because the systems weren't built to understand them," said Fidji Simo, co-founder of ChronicleBio. "ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures." These complex chronic conditions impact nearly 300 million people worldwide, but remain woefully understudied, leaving patients hopeless and without meaningful treatments. It's a disease space desperate for data, and ChronicleBio is offering the scalable solutions to provide it. "Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn't exist at the scale or structure required for serious breakthroughs," said Rohit Gupta, co-founder and CEO of ChronicleBio. "We're empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions." ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the U.S. and India, as well as through research collaborations with thousands of patients contributing data and biosamples. "We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous," said Rishi Reddy, co-founder and Executive Chairman of ChronicleBio. "We're building the foundational infrastructure for a massive medical need that has been hiding in plain sight." ChronicleBio's founding vision isn't just ambitious. It's personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta's family also suffers from neuroimmune disorders. The group's world-class expertise is outshined only by its heartfelt determination to rewrite the scientific narrative for the millions of patients overlooked by traditional research and transform lived experience into actionable discovery. ChronicleBio's approach includes: A global biobank platform collecting and connecting data on neuroimmune illnesses A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians For more information, visit or follow ChronicleBio on LinkedIn, X, Instagram, and Facebook. Media Contact:media@ View original content to download multimedia: SOURCE ChronicleBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Jim Cramer Calls Lincoln Educational a 'Pretty Expensive Stock'
Lincoln Educational Services Corporation (NASDAQ:LINC) is one of the stocks that Jim Cramer spoke about. Responding to a caller's query about the company, Cramer said: 'Oh, it's a pretty expensive stock. I like the concept, but it's up 44%. We got to wait to have it come in.' A technical stock market chart. Photo by Energepic from Pexels Lincoln Educational Services (NASDAQ:LINC) provides career-focused postsecondary education as it offers programs in automotive technology, skilled trades, health sciences, and information technology. On July 7, when a caller asked if the stock is a good long-term investment, Cramer replied: 'Yes, I do. Actually, I do, and I've been thinking about that myself all weekend. That's where you want to be.' The company is expected to release its Q2 earnings on August 11. In Q1, based on the results, the company had raised its full-year guidance. Lincoln Educational Services (NASDAQ:LINC) raised its revenue estimates from $480 million – $490 million to $485 million to – $495 million and net income from $8 million – $13 million to $10 – $15 million. While we acknowledge the potential of LINC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio